30
Participants
Start Date
December 31, 2022
Primary Completion Date
June 30, 2024
Study Completion Date
June 30, 2024
Telitacicept
It is necessary and will be given by subcutaneous injection of 160mg/week for 24 weeks.
Hydroxychloroquine
It is necessary and will be given by oral administration of 0.2g/day for 24 weeks.
Prednisone
It is permitted which can be interchangeable with methylprednisolone. It will be given by oral administration of 30mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
Methylprednisolone
It is permitted which can be interchangeable with prednisone. It will be given by oral administration of 24mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
Cyclophosphamide
It is permitted which can be interchangeable with mycophenolate mofetil or tacrolimus. It will be given by oral administration of 0.8g/month for 24 weeks.
Mycophenolate Mofetil
It is permitted which can be interchangeable with cyclophosphamide or tacrolimus. It will be given by oral administration of 0.5g twice a day for 24 weeks.
Tacrolimus
It is permitted which can be interchangeable with cyclophosphamide or mycophenolate mofetil. It will be given by oral administration of 1mg twice a day for 24 weeks.
RECRUITING
Department of Rheumatology and Immunology, Xiangya Second Hospital, Central South University, Changsha
Fen Li
OTHER